Evaluation of adverse events associated with filgrastim originator and biosimilar using a spontaneous reporting system database.

Niinomi, I; Hosohata, K; Oyama, S; Inada, A; Wakabayashi, T; Iwanaga, K

Niinomi, I; Hosohata, K; Oyama, S; Inada, A; Wakabayashi, T; Iwanaga, K.

Affiliation

Niinomi I; Education and Research Center for Clinical Pharmacy, Osaka University of Pharmaceutical Sciences, Takatsuki, Osaka, Japan.
Hosohata K; Education and Research Center for Clinical Pharmacy, Osaka University of Pharmaceutical Sciences, Takatsuki, Osaka, Japan;, Email: hosohata@gly.oups.ac.jp.
Oyama S; Education and Research Center for Clinical Pharmacy, Osaka University of Pharmaceutical Sciences, Takatsuki, Osaka, Japan.
Inada A; Education and Research Center for Clinical Pharmacy, Osaka University of Pharmaceutical Sciences, Takatsuki, Osaka, Japan.
Wakabayashi T; Education and Research Center for Clinical Pharmacy, Osaka University of Pharmaceutical Sciences, Takatsuki, Osaka, Japan.
Iwanaga K; Education and Research Center for Clinical Pharmacy, Osaka University of Pharmaceutical Sciences, Takatsuki, Osaka, Japan.

Pharmazie ; 75(4): 151-153, 2020 04 06.

Article in En | MEDLINE | ID: mdl-32295692

Subject(s)

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Adverse Drug Reaction Reporting Systems / Biosimilar Pharmaceuticals / Filgrastim / Hematologic Agents Type of study: Risk_factors_studies Limits: Adolescent / Adult / Aged / Aged80 / Child / Female / Humans / Male / Middle aged Language: En Journal: Pharmazie Journal subject: FARMACIA Year: 2020 Document type: Article Affiliation country: Japón Country of publication: Alemania

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google